Neuroregeneration Enhanced by Transcranial Direct Current Stimulation (TDCS) in Stroke (NETS)

Neuroregeneration Enhanced by TDCS in Stroke

Testing the hypothesis that non-invasive brain stimulation by transcranial direct current stimulation (tDCS) combined with functional training in the subacute phase of first-ever stroke will enhance functional regeneration compared with a Placebo intervention.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

Stroke is the leading cause of long-term disability, which significantly impairs the economic and social life of patients and society. Every year 200 000 to 250 000 patients suffer a stroke in Germany. Only a small number of the stroke survivors recover to a degree that allows them to return into their professional and private life. Despite significant efforts to develop novel and efficient treatment strategies the level of functional regeneration is still not satisfying. Thus, the development of innovative and effective treatment strategies will have a major impact for the patients' life, the society and the public health system.

Within the proposed project an innovative, non-invasive and cost effective interventional strategy, based on the combination of a specific rehabilitative training and brain stimulation by transcranial direct current stimulation (tDCS), will be used to enhance functional regeneration in stroke patients. The intervention will be applied in an early stage in which plasticity, cortical reorganization and functional improvement is most pronounced. We hypothesize that the combination of anodal tDCS delivered to the motor cortex of the affected hemisphere combined with training over a period of two weeks in the subacute stage after stroke will significantly enhance cortical plasticity, functional regeneration and long-term outcome determined by clinical and functional outcome measures compared with Placebo stimulation.

Study Type

Interventional

Enrollment (Actual)

119

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Wien, Austria, 1090
        • Neurologische Universitätsklinik Wien
      • Bad Aibling, Germany, 83043
        • Neurologische Klinik Bad Aibling
      • Bad Segeberg, Germany, 23795
        • Neurologisches Zentrum Segeberger Kliniken
      • Bennewitz, Germany, 04828
        • NRZ Leipzig
      • Berlin, Germany, 14089
        • MEDIAN Klinik Berlin-Kladow
      • Hamburg, Germany, 20246
        • University Medical Center Hamburg Eppendorf (UKE)
      • Heidelberg, Germany, 69120
        • University Medical Center Heidelberg
    • Bayern
      • Kipfenberg, Bayern, Germany, 85110
        • Klinik Kipfenberg
    • Berlin
      • Bernau bei Berlin, Berlin, Germany, 16321
        • Brandenburgklinik Berlin-Brandenburg
    • Thüringen
      • Bad Klosterlausnitz, Thüringen, Germany, 07639
        • Neurologie Moritzklinik
      • Rome, Italy, 00179
        • Fondazione Santa Lucia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subacute stroke patients (5-45 days after stroke) with thromboembolic non-hemorrhagic subcortical or cortical, first clinically overt stroke will be included. Moderate to moderately severe upper-extremity hemiparesis, defined as an Upper Extremity Fugl-Meyer score (UEFMA) between 20 and 58 (inclusive).

Exclusion Criteria:

  • pre-existing large lesions (> 1.5 cm maximum diameter) in a brain area that belongs to the anatomically established sensorimotor/premotor system
  • progressive stroke
  • completely lesioned hand knob area of M1 affected if no motor evoked potentials (MEPs) elicited by transcranial magnetic stimulation (TMS) are present
  • bilateral motor impairment
  • florid alcohol and/or drug abuse
  • florid severe psychiatric illness (e.g. schizophrenia)
  • severe language disturbances that prevents the patient to give informed consent or inhibit adequate scoring because of insufficient understanding of scoring introductions
  • tumor diseases with a life expectancy less than one year
  • increased intracranial pressure
  • polyneuropathy and/or ischemic peripheral disease if the sensorimotor functions of the upper extremities are affected clinically relevant
  • severe cognitive deficits (MMSE ≤ 23)
  • pregnancy
  • contraindication for MRI or TMS

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Anodal tDCS
Direct Current (DC)-Stimulator to apply tDCS + Training
Anodal tDCS (20 minutes) stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
Sham Comparator: Sham tDCS
Direct Current (DC)-Stimulator to apply Sham tDCS (Placebo) + Training
Sham stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Upper Extremity Fugl-Meyer-Assessment (UEFMA)
Time Frame: 1-7 days after the end of the intervention
standardized test of upper extremity function
1-7 days after the end of the intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Upper Extremity Fugl-Meyer-Assessment (UEFMA)
Time Frame: 30±10 days after the intervention
standardized test of upper extremity function
30±10 days after the intervention
Upper Extremity Fugl-Meyer-Assessment (UEFMA)
Time Frame: 90±20 days after the intervention
standardized test of upper extremity function
90±20 days after the intervention
Upper Extremity Fugl-Meyer-Assessment (UEFMA) | Long-term outcome
Time Frame: 12±1 months after the intervention
standardized test of upper extremity function
12±1 months after the intervention
Action Research Arm Test (ARAT)
Time Frame: 1-7 days after the end of the intervention
standardized tests of upper extremity function
1-7 days after the end of the intervention
Action Research Arm Test (ARAT)
Time Frame: 30±10 days after the intervention
standardized tests of upper extremity function
30±10 days after the intervention
Action Research Arm Test (ARAT)
Time Frame: 90±20 days after the intervention
standardized tests of upper extremity function
90±20 days after the intervention
Action Research Arm Test (ARAT) | Long-term outcome
Time Frame: 12±1 months after the intervention
standardized tests of upper extremity function
12±1 months after the intervention
Nine Hole Peg Test (NHPT)
Time Frame: 1-7 days after the end of the intervention
standardized test to assess fine motor skills
1-7 days after the end of the intervention
Nine Hole Peg Test (NHPT)
Time Frame: 30±10 days after the intervention
standardized test to assess fine motor skills
30±10 days after the intervention
Nine Hole Peg Test (NHPT)
Time Frame: 90±20 days after the intervention
standardized test to assess fine motor skills
90±20 days after the intervention
Nine Hole Peg Test (NHPT) | Long-term outcome
Time Frame: 12±1 months after the intervention
standardized test to assess fine motor skills
12±1 months after the intervention
Stroke Impact Scale (SIS)
Time Frame: 1-7 days after the end of the intervention
questionnaire is to evaluate how stroke has impacted health and life of patients
1-7 days after the end of the intervention
Stroke Impact Scale (SIS)
Time Frame: 30±10 days after the intervention
questionnaire is to evaluate how stroke has impacted health and life of patients
30±10 days after the intervention
Stroke Impact Scale (SIS)
Time Frame: 90±20 days after the intervention
questionnaire is to evaluate how stroke has impacted health and life of patients
90±20 days after the intervention
Stroke Impact Scale (SIS) | Long-term outcome
Time Frame: 12±1 months after the intervention
questionnaire is to evaluate how stroke has impacted health and life of patients
12±1 months after the intervention
Box-and-Block Test
Time Frame: 1-7 days after the end of the intervention
standardized test to assess fine motor skills
1-7 days after the end of the intervention
Box-and-Block Test
Time Frame: 30±10 days after the intervention
standardized test to assess fine motor skills
30±10 days after the intervention
Box-and-Block Test
Time Frame: 90±20 days after the intervention
standardized test to assess fine motor skills
90±20 days after the intervention
Box-and-Block Test
Time Frame: 12±1 months after the intervention
standardized test to assess fine motor skills
12±1 months after the intervention
Grip Force
Time Frame: 1-7 days after the end of the intervention
dynamometer-based test to assess grip strength
1-7 days after the end of the intervention
Grip Force
Time Frame: 30±10 days after the intervention
dynamometer-based test to assess grip strength
30±10 days after the intervention
Grip Force
Time Frame: 90±20 days after the intervention
dynamometer-based test to assess grip strength
90±20 days after the intervention
Grip Force
Time Frame: 12±1 months after the intervention
dynamometer-based test to assess grip strength
12±1 months after the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Christian Gerloff, Prof. Dr., Department of Neurology, University Medical Center Hamburg-Eppendorf

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2009

Primary Completion (Anticipated)

June 30, 2021

Study Completion (Anticipated)

September 30, 2021

Study Registration Dates

First Submitted

May 12, 2009

First Submitted That Met QC Criteria

May 27, 2009

First Posted (Estimate)

May 28, 2009

Study Record Updates

Last Update Posted (Actual)

May 4, 2021

Last Update Submitted That Met QC Criteria

May 3, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data sharing is planned after main publication of results.

IPD Sharing Time Frame

Within 24 months after main publication.

IPD Sharing Access Criteria

Personal login into UKE data repository.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on DC-Stimulator to apply tDCS

3
Subscribe